ProMIS Historical Financial Ratios
| PMN Stock | USD 0.92 0.11 10.68% |
ProMIS Neurosciences is promptly reporting on over 86 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 0.38, Invested Capital of 592.2 K, Average Payables of 7 M or Stock Based Compensation To Revenue of 54.17 will help investors to properly organize and evaluate ProMIS Neurosciences financial condition quickly.
ProMIS |
About ProMIS Financial Ratios Analysis
ProMIS NeurosciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate ProMIS Neurosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on ProMIS financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across ProMIS Neurosciences history.
ProMIS Neurosciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing ProMIS Neurosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on ProMIS Neurosciences sales, a figure that is much harder to manipulate than other ProMIS Neurosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to ProMIS Neurosciences. There are two different methods for calculating ProMIS Neurosciences invested capital: operating approach and financing approach. Understanding ProMIS Neurosciences invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Revenue Per Share
The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Most ratios from ProMIS Neurosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into ProMIS Neurosciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.At this time, ProMIS Neurosciences' Average Payables is very stable compared to the past year. As of the 27th of November 2024, Interest Coverage is likely to grow to 98.53, while Price To Sales Ratio is likely to drop 5,071.
| 2023 | 2024 (projected) | Net Current Asset Value | 583.44 | 518.62 | Days Payables Outstanding | 363.15 | 381.3 |
ProMIS Neurosciences fundamentals Correlations
Click cells to compare fundamentals
ProMIS Neurosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ProMIS Neurosciences fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 187.2K | 47.6K | 20.8K | 5.9K | 5.3K | 5.1K | |
| Ptb Ratio | 110.07 | (28.69) | 6.74 | (17.84) | 2.84 | 2.7 | |
| Book Value Per Share | 0.0919 | (0.21) | 1.24 | 0.0923 | 0.4 | 0.38 | |
| Operating Cash Flow Per Share | (1.08) | (0.72) | (1.6) | (2.27) | (1.17) | (1.23) | |
| Stock Based Compensation To Revenue | 2.3K | 538.6 | 146.53 | 63.36 | 57.02 | 54.17 | |
| Pb Ratio | 110.07 | (28.69) | 6.74 | (17.84) | 2.84 | 2.7 | |
| Ev To Sales | 180.3K | 45.8K | 20.1K | 3.9K | 3.5K | 3.3K | |
| Free Cash Flow Per Share | (1.59) | (1.08) | (0.74) | (2.27) | (1.17) | (1.23) | |
| Roic | (14.22) | 4.37 | (0.71) | 9.04 | (3.76) | (3.95) | |
| Net Income Per Share | (1.31) | (0.93) | (1.67) | (1.7) | (1.42) | (1.5) | |
| Sales General And Administrative To Revenue | 5.8K | 2.2K | 1.4K | 407.11 | 366.4 | 348.08 | |
| Average Inventory | (35.6K) | (38.4K) | (48.5K) | (43.9K) | (50.5K) | (48.0K) | |
| Research And Ddevelopement To Revenue | 15.6K | 3.9K | 1.8K | 608.1 | 547.29 | 519.93 | |
| Cash Per Share | 0.39 | 0.23 | 3.71 | 1.07 | 1.36 | 1.29 | |
| Pocfratio | (9.4) | (8.53) | (5.2) | (1.91) | (0.98) | (1.03) | |
| Pfcf Ratio | (9.4) | (8.33) | (5.2) | (1.91) | (0.98) | (1.03) | |
| Income Quality | 0.85 | 0.82 | 0.77 | 1.0 | 0.94 | 0.66 | |
| Roe | (14.22) | 4.37 | (1.35) | 6.98 | (3.52) | (3.7) | |
| Ev To Operating Cash Flow | (9.04) | (8.23) | (3.42) | (1.44) | 0.18 | 0.19 | |
| Pe Ratio | (7.74) | (6.56) | (5.0) | (2.55) | (0.81) | (0.85) | |
| Return On Tangible Assets | (2.8) | (3.31) | (0.43) | (1.36) | (0.97) | (1.02) | |
| Ev To Free Cash Flow | (9.04) | (8.03) | (3.42) | (1.44) | 0.18 | 0.19 | |
| Earnings Yield | (0.13) | (0.15) | (0.2) | (0.39) | (1.24) | (1.18) | |
| Intangibles To Total Assets | 0.0233 | 0.0301 | 0.001556 | 0.003009 | 0.003461 | 0.003288 | |
| Current Ratio | 1.21 | 0.52 | 19.07 | 1.08 | 1.46 | 1.38 | |
| Tangible Book Value Per Share | 0.0808 | (0.22) | 1.23 | 0.0886 | 0.4 | 0.38 |
Pair Trading with ProMIS Neurosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with ProMIS Stock
| 0.84 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.62 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against ProMIS Stock
| 0.76 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.74 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.54 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.52 | PHVS | Pharvaris BV | PairCorr |
| 0.5 | PMVP | Pmv Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.